The role of etanercept in the treatment of patients with severe rheumatoid arthritis

Abstract

The article is devoted to the use of a tumor-necrosis-factor-alpha inhibitor etanercept in patients with severe rheumatoid arthritis. The author examines various aspects of therapy with genetically engineered biologic drugs (GEBD), in particular the issues of efficiency and safety, the possibility of monotherapy, antidestructive effect of the drug, etc.

Keywords

• ревматоидный артрит
• генно-инженерные биологические препараты
• ингибиторы фактора некроза опухоли альфа
• этанерцепт
• rheumatoid arthritis
• genetically engineered biologic drugs
• tumor-necrosis-factor-alpha inhibitors
• etanercept